Cargando…

Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with limited treatment options. Recently, there has been a growing interest in immunotherapy with immune checkpoint inhibitors (ICIs) in TNBC, leading to extensive preclinical and clinical research. This review summari...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uchimiak, Katarzyna, Badowska-Kozakiewicz, Anna M., Sobiborowicz-Sadowska, Aleksandra, Deptała, Andrzej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201309/ https://www.ncbi.nlm.nih.gov/pubmed/35721387 http://dx.doi.org/10.1177/11795549221099869

Ejemplares similares

Medullary breast cancer is a predominantly triple-negative breast cancer – histopathological analysis and comparison with invasive ductal breast cancer
por: Budzik, Michał P., et al.
Publicado: (2019)

Clinicopathological factors associated with novel prognostic markers for patients with triple negative breast cancer
por: Badowska-Kozakiewicz, Anna M., et al.
Publicado: (2018)

Assessment of Pain, Acceptance of Illness, Adjustment to Life, and Strategies of Coping with Illness among Patients with Gastric Cancer
por: Religioni, Urszula, et al.
Publicado: (2019)

Assessment of Pain, Acceptance of the Disease, Adaptation to Life and Strategies for Coping with the Disease among Patients with Ovarian Cancer
por: Religioni, Urszula, et al.
Publicado: (2021)

New Treatment Options in Metastatic Pancreatic Cancer
por: Fudalej, Marta, et al.
Publicado: (2023)

Evaluation of Nutritional Status and the Impact of Nutritional Treatment in Patients with Pancreatic Cancer
por: Mękal, Dominika, et al.
Publicado: (2023)

The complexity of tumour angiogenesis based on recently described molecules
por: Wiśniewska, Weronika, et al.
Publicado: (2021)

What is new about ovarian malignancies?
por: Grabska, Kinga, et al.
Publicado: (2021)

How A Patient with Resectable or Borderline Resectable Pancreatic Cancer should Be Treated—A Comprehensive Review
por: Kwaśniewska, Daria, et al.
Publicado: (2023)

Cancer-associated inflammation: pathophysiology and clinical significance
por: Pęczek, Piotr, et al.
Publicado: (2022)

Rare Non-Neuroendocrine Pancreatic Tumours
por: Mormul, Agata, et al.
Publicado: (2023)

Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity
por: Sobiborowicz-Sadowska, Aleksandra M., et al.
Publicado: (2023)

Diabetes Mellitus and Pancreatic Ductal Adenocarcinoma—Prevalence, Clinicopathological Variables, and Clinical Outcomes
por: Badowska-Kozakiewicz, Anna, et al.
Publicado: (2022)

Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
por: Heeke, Arielle L., et al.
Publicado: (2021)

Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
por: Abdou, Yara, et al.
Publicado: (2022)

Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer
por: Simmons, Christine E., et al.
Publicado: (2020)

Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges
por: Poggi, Alessandro, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker
por: Qureshi, Sadaf, et al.
Publicado: (2022)

Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer
por: Sardela de Miranda, Flávia, et al.
Publicado: (2023)

Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions
por: Thouvenin, Jonathan, et al.
Publicado: (2021)

Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
por: Yi, Huimei, et al.
Publicado: (2021)

Civil Lawsuits as an Indicator of Adverse Outcomes in Healthcare
por: Mikos, Marcin, et al.
Publicado: (2022)

Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
por: Mediratta, Karan, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
por: Thomas, Remy, et al.
Publicado: (2021)

The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge
por: Temian, Daiana Cosmina, et al.
Publicado: (2018)

Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance
por: Kim, Hyungjoo, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
por: Liu, Hao-Tian, et al.
Publicado: (2021)

Quality of Life in Patients with Pancreatic Cancer—A Literature Review
por: Cipora, Elżbieta, et al.
Publicado: (2023)

MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance
por: Mehlich, Dawid, et al.
Publicado: (2021)

Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
por: Gan, Lu, et al.
Publicado: (2022)

RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer
por: Tentler, John J., et al.
Publicado: (2020)

Potential predictive value of circulating tumor DNA (ctDNA) mutations for the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer
por: Tan, Qiaorui, et al.
Publicado: (2023)

Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives
por: Welti, Michèle, et al.
Publicado: (2022)

Immunohistochemical characteristics of basal-like breast cancer
por: Badowska-Kozakiewicz, Anna M., et al.
Publicado: (2017)

Current shreds of evidence on the anticancer role of EGCG in triple negative breast cancer: an update of the current state of knowledge
por: Bimonte, Sabrina, et al.
Publicado: (2020)

Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer
por: Tan, Qiaorui, et al.
Publicado: (2022)

LCOR Reverses Immune-Checkpoint Inhibitors Therapy Resistance Out of IFN Constraint in Triple-Negative Breast Cancer
por: Zhou, Jialin, et al.
Publicado: (2022)

Opioids and immune checkpoint inhibitors differentially regulate a common immune network in triple-negative breast cancer
por: Scarpa, Joseph R., et al.
Publicado: (2023)

Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Li, Yunhai, et al.
Publicado: (2021)

Immune checkpoints: A therapeutic target in triple negative breast cancer
por: Chawla, Akhil, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_u2q87uqqvl5m18428g65pu7oas